<a href="https://www.fiercebiotech.com/biotech/ose-turns-heat-ovarian-cancer-phase-2-keytruda-supported-win" hreflang="en">OSE turns up the heat on ovarian cancer with phase 2, Keytruda-supported win</a>
OSE Immunotherapeutics reported positive phase 2 trial results for its neo-epitope vaccine candidate, OSE2101, in combination with Keytruda for recurrent ovarian cancer, showing improved progression-free survival compared to best supportive care. The study indicates that the combination therapy may enhance treatment outcomes, particularly for patients who previously responded to platinum therapy, although further research is needed to clarify the contributions of each component.
OSE Immunotherapeutics' phase 2 trial results for their neo-epitope vaccine candidate in combination with Keytruda show a statistically significant improvement in progression-free survival for recurrent ovarian cancer patients compared to best supportive care. This highlights the potential of combining immune-modulating vaccines with checkpoint inhibitors to enhance treatment efficacy in cancers with traditionally poor outcomes. As OSE advances into phase 3 trials for other cancers, this development may signal opportunities for further investment and collaboration in the immunotherapy space.